Lanean...
Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
PURPOSE: Oncotype DX (ODX) recurrence score (RS) breast cancer (BC) assay is costly, and performed in only ~1/3 of estrogen receptor (ER)-positive BC patients in the USA. We have now developed a user-friendly nomogram surrogate prediction model for ODX based on a large dataset from the National Canc...
Gorde:
| Argitaratua izan da: | Breast Cancer Res Treat |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Springer US
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5387031/ https://ncbi.nlm.nih.gov/pubmed/28243897 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4170-3 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|